Jacobus Pharmaceutical Recalls Ruzurgi Tablets Due to Potential Contamination of Yeast, Mold, and Aerobic Bacteria

Jacobus Pharmaceutical Company recalled three lots of Ruzurgi (amifampridine) 10-mg tablets due to potential health risk.

Laboratory tests found that the product is contaminated with yeast, mold, and aerobic bacteria that may cause serious and life-threatening infections.

The use of the defective product in patients with underlying immunosuppressive conditions such as Lambert Eaton Syndrome (LEMS) increases the concern for serious infections.

The recalled product, which is used as a treatment for Lambert Eaton Syndrome (LEMS) in patients ages 6 to less than 17, is packaged in 100 count bottles (NDC: 49938-110-01) with the following control numbers and expiration dates:

  • Control Number 18038, Expiration 03/2023, distributed between 05/25/2021 – 08/26/2021 (Canada only).
  • Control Number 18039, Expiration 03/2023, distributed between 06/01/2021 – 08/10/2021.
  • Control Number 18079, Expiration 05/2023, distributed between 08/10/2021 – 08/30/2021

The Control Number is located to the right of the bottle’s front panel below the D2 Barcode.

The company urges consumers who have the recalled product should stop using and return it as soon as possible.

There have been no reported illness to date.

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.